Detalles de la búsqueda
1.
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
Oncologist
; 26(4): e632-e638, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33393112
2.
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Pancreatology
; 21(1): 192-199, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33214082
3.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Oncologist
; 24(4): 463-474, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30355775
4.
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Oncologist
; 23(1): 16-24, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29038234
5.
Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Pituitary
; 21(3): 283-289, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29357081
6.
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Endocr Pract
; 24(3): 243-255, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29547049
7.
BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Endocr Pract
; 2018 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30084687
8.
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.
Pituitary
; 20(6): 605-618, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28741071
9.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 380(9839): 358-65, 2012 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22735384
10.
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
N Engl J Med
; 358(11): 1109-17, 2008 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-18337601
11.
A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
Patient Relat Outcome Meas
; 10: 335-343, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31754316
12.
Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
J Gastrointest Cancer
; 50(4): 816-823, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121904
13.
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Cancers (Basel)
; 11(8)2019 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31357748
14.
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
J Geriatr Oncol
; 10(3): 427-435, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30842038
15.
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Eur J Cancer
; 108: 78-87, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30654298
16.
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.
J Gastrointest Oncol
; 10(4): 674-687, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31392048
17.
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States.
Pancreas
; 47(2): 173-182, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29206668
18.
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.
Endocrine
; 61(1): 105-117, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29767287
19.
Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.
Clinicoecon Outcomes Res
; 9: 495-503, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28860831
20.
A desensitization protocol for the mAb cetuximab.
J Allergy Clin Immunol
; 123(1): 260-2, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19022494